When should we stop intravesical treatment in patients with superficial bladder cancer?
von Heyden
B
B
Urologische Klinik, RWTH Aachen, FRG.
Jakse
G
G
D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000188:drug therapy; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents